Thought Leadership - 04.08.2021
White Paper: Developing Advanced Therapies – Considerations for Internal Versus External Manufacturing
Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.
This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).
Gain key insights in their respective fields of investment management; manufacturing and technical operations; global pricing; and commercialization, advocacy, and legislation provided a distinctive perspective on how to approach manufacturing and other roadblocks at every stage of development.
Download our free white paper now to learn more.